Iovance Biotherapeutics enters the week of July 18 carrying one of the more interesting tensions in small-cap biotech: a stock up 31% in a month, yet still carrying 26% of its free float sold short — and shorts have been covering fast.
The short interest story is the main event right now. At 26.1% of free float, the short position remains heavily elevated, but the directional move is what stands out — shares short fell roughly 16% over the past week, dropping from around 121 million to just over 103 million. That's a meaningful cover, and it coincides almost exactly with the price rally. Borrow availability has loosened to around 74%, up from the low-60s earlier in the week, as returned shares re-enter the lending pool. Cost to borrow remains cheap at under 1%, so this doesn't look like a forced squeeze driven by borrow scarcity — it looks more like discretionary covering into a rising tape. The ORTEX short score at 76 is still elevated in absolute terms, ranking in just the 6th percentile for short score (meaning the stock ranks among the most shorted names in the universe), but the score has ticked down from 78 earlier in the week, consistent with the covering trend.
Options traders are leaning bullish, adding weight to the covering narrative. The put/call ratio has drifted to 0.27, running nearly 1.7 standard deviations below its 20-day average of 0.28 — which sounds like a small gap until you note that the 20-day standard deviation here is unusually tight, meaning even a modest directional tilt registers as statistically notable. The 52-week PCR range spans 0.10 to 0.37, and the current reading near the lower end signals that call activity is clearly dominant. Options positioning and short covering are telling the same story: participants are reducing downside exposure.
The analyst picture is harder to read cleanly. The consensus is a hold, with the most recent changes coming from May — Chardan Capital trimmed its target to $14 while keeping a Buy, and UBS had raised its Neutral target to $4 back in March. With the stock now at $5.00, the UBS $4 target is already below the current price, and Chardan's $14 target, while bullish in direction, is dated enough to treat with caution. Barclays holds an Overweight with an $11 target, last updated in February. The bull case centres on Amtagvi's commercial ramp and potential for a 2027 U.S. approval in an additional indication; the bear case flags execution risk on manufacturing and ongoing cash burn — the EV/EBITDA sits at -9.6 and the price/book is 3.3, with no earnings yield to speak of. The EPS surprise factor score ranks in the 79th percentile, suggesting the company has been beating lowered estimates consistently, but 30-day EPS momentum sits in just the 14th percentile. Institutional flows offer some support: BlackRock added 2.2 million shares through June 30, and State Street added a substantial 6.4 million shares in the same window.
Earnings are due August 6. The prior print in May produced an 11% single-day decline followed by a 14% five-day drawdown. The print before that, in June, added just over 2% on the day. With shorts having covered aggressively into this rally, the setup heading into Q2 results will be worth tracking — specifically whether the remaining 26% short base stays put or continues to unwind ahead of the announcement.
See the live data behind this article on ORTEX.
Open IOVA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
